tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ARWR Stock Latest News

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 Earnings Cheat Sheet
Pre-EarningsArrowhead Pharmaceuticals, Inc. (ARWR) Q4 Earnings Cheat Sheet
36m ago
ARWR
Arrowhead price target raised to $48 from $27 at Goldman Sachs
PremiumThe Fly
Arrowhead price target raised to $48 from $27 at Goldman Sachs
3d ago
ARWR
IONS
Arrowhead price target raised to $52 from $45 at RBC Capital
PremiumThe Fly
Arrowhead price target raised to $52 from $45 at RBC Capital
4d ago
ARWR
Arrowhead price target raised to $70 from $45 at Piper Sandler
PremiumThe Fly
Arrowhead price target raised to $70 from $45 at Piper Sandler
4d ago
ARWR
Arrowhead Pharmaceuticals: Strong Market Position and Growth Potential with REDEMPLO’s FDA Approval
PremiumRatings
Arrowhead Pharmaceuticals: Strong Market Position and Growth Potential with REDEMPLO’s FDA Approval
4d ago
ARWR
Arrowhead Pharmaceuticals: Hold Rating Amid Market Challenges and Future Opportunities
PremiumRatingsArrowhead Pharmaceuticals: Hold Rating Amid Market Challenges and Future Opportunities
4d ago
ARWR
Arrowhead Pharmaceuticals’ REDEMPLO Approved by FDA
Premium
Company Announcements
Arrowhead Pharmaceuticals’ REDEMPLO Approved by FDA
5d ago
8K
ARWR
Arrowhead trading resumes
Premium
The Fly
Arrowhead trading resumes
5d ago
ARWR
Arrowhead announces FDA approval of Redemplo for FCS
PremiumThe Fly
Arrowhead announces FDA approval of Redemplo for FCS
5d ago
ARWR
Arrowhead’s plozasiran approved by FDA in familial chylomicronemia syndrome
PremiumThe Fly
Arrowhead’s plozasiran approved by FDA in familial chylomicronemia syndrome
5d ago
ARWR
Arrowhead trading halted, news pending
PremiumThe Fly
Arrowhead trading halted, news pending
5d ago
ARWR
REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?
PremiumMarket News
REGN, GMAB, ARWR: Which Healthcare Stock Is Best Buy Ahead of U.S. Drug Approvals This Nov?
9d ago
NVS
ARWR
Arrowhead price target raised to $45 from $29 at Morgan Stanley
PremiumThe FlyArrowhead price target raised to $45 from $29 at Morgan Stanley
11d ago
ARWR
IONS
Arrowhead Pharmaceuticals Advances Alzheimer’s Treatment with New Clinical Study
Premium
Company Announcements
Arrowhead Pharmaceuticals Advances Alzheimer’s Treatment with New Clinical Study
26d ago
ARWR
Arrowhead Pharmaceuticals Advances Cholesterol Treatment with Phase 3 Study
Premium
Company Announcements
Arrowhead Pharmaceuticals Advances Cholesterol Treatment with Phase 3 Study
26d ago
ARWR
Arrowhead Pharmaceuticals Advances in FSHD1 Treatment with ARO-DUX4 Study
PremiumCompany Announcements
Arrowhead Pharmaceuticals Advances in FSHD1 Treatment with ARO-DUX4 Study
26d ago
ARWR
Arrowhead Pharmaceuticals Advances Plozasiran Study for Hypertriglyceridemia
PremiumCompany Announcements
Arrowhead Pharmaceuticals Advances Plozasiran Study for Hypertriglyceridemia
26d ago
ARWR
Arrowhead Pharmaceuticals Advances in SCA2 Treatment with ARO-ATXN2 Study
PremiumCompany Announcements
Arrowhead Pharmaceuticals Advances in SCA2 Treatment with ARO-ATXN2 Study
27d ago
ARWR
Arrowhead Pharmaceuticals’ ARO-INHBE Study: A Potential Game-Changer in Obesity Treatment
PremiumCompany Announcements
Arrowhead Pharmaceuticals’ ARO-INHBE Study: A Potential Game-Changer in Obesity Treatment
27d ago
ARWR
Arrowhead Pharmaceuticals’ ARO-ALK7 Study: A Potential Game-Changer in Obesity Treatment
PremiumCompany AnnouncementsArrowhead Pharmaceuticals’ ARO-ALK7 Study: A Potential Game-Changer in Obesity Treatment
27d ago
ARWR
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Severe Hypertriglyceridemia
Premium
Company Announcements
Arrowhead Pharmaceuticals Advances Phase 3 Study on Plozasiran for Severe Hypertriglyceridemia
27d ago
ARWR
Arrowhead Pharmaceuticals Advances ARO-DM1 Study for Myotonic Dystrophy
Premium
Company Announcements
Arrowhead Pharmaceuticals Advances ARO-DM1 Study for Myotonic Dystrophy
27d ago
ARWR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >